Side-by-side · Research reference
CagrilintidevsSemaglutide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 3HUMAN-REVIEWED35/64 cited
BFDA-ApprovedFlagship15/53 cited
Semaglutide
GLP-1 RA · FDA-Approved
SQ · Abdomen / thigh / arm · Once weekly
01Mechanism of Action
Parameter
Cagrilintide
Semaglutide
Primary target
Amylin receptor (AMYR) and calcitonin receptor (CTR) heterodimeric complexesBailey 2026
GLP-1 receptor (GLP-1R)WEGOVY (semaglutide) injection 2021
Pathway
AMYR/CTR agonism → Central satiety signaling → Reduced food intake, delayed gastric emptying, suppressed glucagonBailey 2026
GLP-1R agonism → ↑glucose-dependent insulin secretion, ↓glucagon, ↓gastric emptying, ↓appetite via hypothalamic centres
Downstream effect
Central satiety induction, prandial glucagon suppression, reduced caloric intake, weight loss, improved glycemic controlBailey 2026Yamauchi 2026
Improved glycemic control, reduced caloric intake, body-weight reduction, cardiovascular risk reductionWilding 2021
Feedback intact?
Yes — acts via physiological amylin pathways
Glucose-dependent insulin release preserves physiological feedback
Origin
Second-generation non-aggregating long-acting amylin analogue designed for once-weekly dosingBailey 2026
Modified GLP-1(7-37) with two amino-acid substitutions and C-18 fatty-acid acylation for albumin binding and 168-h half-lifeWEGOVY (semaglutide) injection 2021
Antibody development
—
—
02Dosage Protocols
Parameter
Cagrilintide
Semaglutide
Standard dose (combination)
Cagrilintide 2.4 mg + Semaglutide 2.4 mg (CagriSema)Yamauchi 2026
Phase 3 REDEFINE 5 trial dosing.
—
Monotherapy dosing
Dose-dependent, under investigation
Monotherapy trials reported in meta-analysis.
—
Frequency
Once weekly (subcutaneous)Bailey 2026
Long-acting formulation.
Once weekly, same day each week
Evidence basis
Phase 3 RCT (REDEFINE 5), meta-analysis of 3 RCTs (n=3545)Yamauchi 2026Ahmed 2026
FDA-approved · Phase 3 RCTsWilding 2021WEGOVY (semaglutide) injection 2021
Duration
26–52 weeks in trialsYamauchi 2026
Indefinite for chronic indication
Discontinuation results in weight regain.
Standard dose (weight, Wegovy)
—
2.4 mg / week (after 16-wk titration)WEGOVY (semaglutide) injection 2021Wilding 2021
Titration schedule
—
0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg over 16 weeks
Mitigates GI side effects.
Reconstitution
—
Pre-mixed pen device (commercial). Research lyophilised vial: bacteriostatic water per label.
Timing
—
Any time of day, with or without food
03Metabolic / Fat Loss Evidence
Parameter
Cagrilintide
Semaglutide
Weight loss vs semaglutide
7.47% greater percentage weight lossAhmed 2026
CagriSema combination vs semaglutide monotherapy (meta-analysis).
—
Absolute weight change
Significantly greater absolute weight reductionAhmed 2026
Mean difference favoring combination therapy.
—
Glycemic benefit
Reduced fasting glucose and HbA1cAhmed 2026
Synergistic effect with semaglutide in combination.
—
Body composition
Predominant fat loss with weight reduction
—
Mitochondrial function
In vitro effects on skeletal muscle mitochondria under metabolic stress conditionsOld 2026
C2C12 myotube study; clinical relevance under investigation.
—
Key publications
REDEFINE 5 (Yamauchi 2026) · Ahmed meta-analysis 2026 · Bailey review 2026Yamauchi 2026Ahmed 2026Bailey 2026
—
04Side Effects & Safety
Parameter
Cagrilintide
Semaglutide
Gastrointestinal
Nausea, diarrhea (common with incretin-based therapies)Pardali 2026
Dietary management and nutritional monitoring recommended.
—
Injection site reactions
Local reactions possible with subcutaneous administration
—
Safety profile
Generally consistent with incretin-based therapies
Phase 3 and meta-analysis safety data.
—
Tolerability
Tolerability considerations similar to GLP-1RAs
—
Muscle preservation
Lean mass considerations during weight loss
In vitro mitochondrial effects observed; clinical impact under investigation.
—
Injection site reaction
—
Mild erythema, pruritus
Thyroid C-cell tumours
—
Boxed warning — contraindicated in MEN2 / personal or family MTC historyWEGOVY (semaglutide) injection 2021
Hypoglycemia
—
Low risk as monotherapy; elevated when combined with sulfonylureas / insulin
Gallbladder events
—
Increased cholelithiasis
Heart rate
—
Modest ↑ resting HR (~2-4 bpm)
Absolute Contraindications
Cagrilintide
- ·Hypersensitivity to cagrilintide or formulation components
Semaglutide
- ·Personal or family history of medullary thyroid carcinoma
- ·Multiple endocrine neoplasia syndrome type 2
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to semaglutide
Relative Contraindications
Cagrilintide
- ·Severe gastrointestinal disease
- ·History of pancreatitis (incretin-based therapy consideration)
Semaglutide
- ·Severe gastroparesis
- ·History of pancreatitis
- ·Diabetic retinopathy (may worsen with rapid glycemic improvement)
05Administration Protocol
Parameter
Cagrilintide
Semaglutide
1. Dosing frequency
Once-weekly subcutaneous injection. Long-acting formulation designed for weekly administration schedule.Bailey 2026
Commercial: pre-filled pen, no reconstitution. Research vial: per-label or bacteriostatic water.
2. Combination form
Co-formulated with semaglutide as CagriSema for single weekly injection combining amylin and GLP-1 receptor agonism.Yamauchi 2026Bailey 2026
SQ — abdomen, thigh, or upper arm. Rotate sites weekly to avoid lipohypertrophy.
3. Injection site
Subcutaneous — typically abdomen, thigh, or upper arm. Rotate injection sites weekly to minimize local reactions.
Once weekly, same day. Day can be changed if ≥2 days separate doses.
4. Storage
Refrigerate 2–8°C. Follow product-specific storage instructions for pre-filled pens or vials. Protect from light.
Pen: refrigerate 2–8 °C unopened; room temp ≤30 °C up to 56 days after first use.
5. Dietary considerations
Nutritional monitoring recommended during treatment. Dietary management strategies important for tolerability and outcomes.Pardali 2026
Pen-supplied 31–34G needle. Research vial: 27–31G insulin syringe.
06Stack Synergy
Cagrilintide
+ Semaglutide
StrongCagrilintide (amylin receptor agonist) and semaglutide (GLP-1 receptor agonist) act on distinct receptor systems to produce synergistic weight loss through complementary mechanisms — central satiety via amylin pathways plus incretin-mediated glucose control and appetite suppression via GLP-1. Co-formulated as CagriSema, this combination demonstrates 7.5% greater weight loss versus semaglutide monotherapy in Phase 3 trials with additional benefits on glycemic control and lipid parameters.
- CagriSema
- Cagrilintide 2.4 mg + Semaglutide 2.4 mg
- Frequency
- Once weekly subcutaneous
- Duration
- 26–52 weeks (trial data)
- Primary benefit
- Enhanced weight loss, improved glycemic control, multi-pathway metabolic modulation
Semaglutide
+ Tirzepatide
WeakCombining two GLP-1 RA-class drugs is not clinically validated and risks additive GI toxicity. Tirzepatide's GIP component already provides complementary mechanism vs pure GLP-1; stacking with semaglutide adds receptor saturation but no synergy. NOT recommended.
- Note
- Stack not recommended — choose one GLP-1 RA
- Primary benefit
- (none — additive toxicity, no synergy)